PPD Honored for Best Technology in Clinical Research

Scrip Award recognizes groundbreaking solution improving training for clinical trial monitoring

WILMINGTON, N.C., (November 29, 2012) – Pharmaceutical Product Development, LLC (PPD) today announced it has been recognized by Scrip Intelligence with its 2012 award for Best Technological Development in Clinical Trials for deploying cutting-edge solutions advancing clinical research.

PPD received the honor at the annual Scrip Awards ceremony Nov. 28 in London, marking the second consecutive year PPD won for best technology after receiving the 2011 Scrip Award for Best Contract Research Organization (CRO).

“Winning this award for the second consecutive year is a testament to the people of PPD,” said David Simmons, chairman and CEO of PPD. “In today’s evolving health care model, CROs must be able to adapt to clients’ changing needs and proactively meet their challenges. PPD connects talented people and innovative solutions to exceed the needs of our biopharmaceutical industry clients, who are constantly seeking ways to increase productivity and efficiency.”

The Scrip Award for best technology recognized PPD® 3D, a virtual learning environment PPD created with ProtonMedia to provide a scalable and sustainable global training model. PPD 3D improves how PPD trains clinical research associates to monitor clinical trials, which is vital for enhancing the quality of site management and clinical monitoring for clients’ research programs, and can contribute to faster project startup.

“PPD were worthy winners of this award,” said Mike Ward, chief content officer for Datamonitor Healthcare and Scrip Intelligence. “Their PPD 3D technology has improved the cost-effectiveness, speed and quality of clinical trial training for the life sciences, and our judges were impressed by the novel use of this type of technology in clinical research, saying it has huge potential.”

The Scrip Awards acknowledge achievements across a broad range of areas in the biopharmaceutical industry. Attracting hundreds of industry professionals from the world’s leading pharmaceutical and biotechnology companies, the awards have become a distinct mark of superior achievement. Pharmaceutical, biotech and contract research organizations compete for awards in 15 categories, which are decided by an expert panel of judges.

About PPD
PPD is a leading global contract research organization providing drug discovery, development and lifecycle management services. Our clients and partners include pharmaceutical, biotechnology,
medical device, academic and government organizations. With offices in 46 countries and more than 12,000 professionals worldwide, PPD applies innovative technologies, therapeutic expertise and a commitment to quality to help clients and partners accelerate the delivery of safe and effective therapeutics and maximize the returns on their R&D investments. For more information, visit www.ppdi.com.

Except for historical information, all of the statements, expectations and assumptions, including statements, expectations and assumptions about PPD's Scrip recognition, contained in this news release are forward-looking statements that involve a number of risks and uncertainties. Although PPD attempts to be accurate in making these forward-looking statements, it is possible that future circumstances might differ from the assumptions on which such statements are based and could cause actual results to differ materially from the forward-looking statements. Other important factors that could cause future results to differ materially include the following: competition in the outsourcing industry; the ability to attract, integrate and retain key personnel, including our chairman and CEO; rapid technological advances that make our services less competitive; overall global economic conditions; economic conditions, research and development spending, and outsourcing trends in the pharmaceutical, biotechnology and government-sponsored research sectors; consolidation in the pharmaceutical and biotechnology industries; PPD's ability to win new business; loss, delay or modification of large contracts; higher-than-expected cancellation rates; the rate of conversion of backlog into revenue; actual operating performance; risks associated with and dependence on strategic relationships; risks associated with acquisitions and investments; the ability to control SG&A spending; compliance with drug development regulations; and changes in the regulation of the drug development process. PPD assumes no obligation and expressly disclaims any duty to update these forward-looking statements in the future, except as required by applicable law. These forward-looking statements should not be relied upon as representing PPD's estimates or views as of any date subsequent to the date hereof.